INTRODUCTION
Results of recent clinical trials have intensified interest in immunotherapy for prostate cancer. The primary aim of immunotherapy is to harness the immune system's ability to recognize and destroy tumor cells. Prostate cancer is particularly well suited for immunotherapeutic approaches for three reasons. 1 First, early detection, along with the relatively indolent clinical course of prostate cancer, allows sufficient time to generate immune responses that may take weeks or months to mount. Second, prostate cancer cells express several tumor-associated antigens (TAAs), such as prostate-specific antigen (PSA), prostatic acid phosphatase (PAP) and prostate-specific membrane antigen, which can serve as targets for activated immune cells. [2] [3] [4] Finally, since the prostate is a nonessential organ, eradication of residual normal prostate tissue as a result of the immune response has no clinical sequelae.
Current strategies at the forefront of immunotherapy for prostate cancer include therapeutic vaccines and immune checkpoint inhibitors. Therapeutic cancer vaccines are designed to stimulate immune cells to target specific TAAs overexpressed on cancer cells and are associated with minimal toxicity. Antigen-presenting cells (APCs) present antigens to the immune system via major histocompatibility complex molecules, which bind to appropriate T-cell receptors. Activated T cells travel to the tumor, which they recognize by way of the TAAs presented in the context of the major histocompatibility complex, leading to T cell-mediated killing of tumor cells or immunogenic cell death. Unlike standard cancer treatments, immunotherapeutic effects
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Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications processing facility where CD54 + APCs are pulsed with PA2024, a fusion protein consisting of PAP linked to the immunomodulatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF). 11, 12 The vaccine product must meet a minimum threshold of CD54 expression before it can be released for use. The vaccine is then infused into the patient three times at biweekly intervals. Promising early clinical data led to a pair of small phase III trials in which the primary endpoint was time to progression (TTP), with overall survival (OS) as a planned secondary endpoint. 13, 14 In each trial, men with asymptomatic or minimally symptomatic mCRPC were randomly assigned 2:1 to receive either sipuleucel-T or a placebo not pulsed with PA2024. Analysis of the 225 men from both trials showed no improvement in TTP, but a consistent benefit in OS relative to placebo (23.2 vs 18.9 months, hazard ratio (HR), 0.67, 95% confidence interval (CI) 0.49-0.91).
These results led to a larger phase III trial (IMPACT; n = 512) with OS as the primary endpoint rather than TTP. At a median follow-up of 34 months, patients treated with sipuleucel-T showed significantly improved OS compared with placebo (25.8 vs 21.7 months; HR, 0.78; 95% CI, 0.61-0.98). As in the earlier trials, there was no significant change in time to radiographic or PSA progression and few declines in PSA. 15 Patients treated with sipuleucel-T had less disease-related pain; a retrospective data analysis detected delayed median time to first use of opioid analgesics compared to patients given placebo (11.9 vs 8.3 months; HR, 0.73; 95% CI, 0.54-0.99). 16 A subgroup analysis showed activation of APCs through upregulation of CD54, as well as antibodies and T-cell proliferation responses to PAP and PA2024. An immunologic assessment of patients in the three sipuleucel-T trials suggested that patients with more potent immune responses post-vaccination showed the greatest improvement in OS. 17 Research demonstrating the biologic activity of neoadjuvant sipuleucel-T preradical prostatectomy has been revealing. Prostatectomy specimens from vaccinated patients showed a greater than twofold increase in CD3 + and CD4 + T cells at the tumor interface, suggesting that immune cells travel to the prostate and are active in disease control. 18 Furthermore, a retrospective analysis of the IMPACT trial found that patients in the lowest quartile of baseline PSA values received the greatest benefit from the vaccine, with a 13-month improvement in median OS (41.3 months with sipuleucel-T vs 28.3 months with placebo; HR, 0.51; 95% CI, 0.31-0.85). In contrast, patients in the highest baseline PSA quartile had a median OS of 18.4 vs 15.6 months for placebo (HR, 0.84; 95% CI, 0.55-1.29), an improvement of only 2.8 months. 19 These results support the use of sipuleucel-T in earlier-stage disease. 20 In all three trials, sipuleucel-T was well-tolerated, with minimal toxicity. Injection-site reactions, transient fever and flu-like symptoms were most frequently reported.
PSA-TRICOM (PROSTVAC-VF ® )
PSA-TRICOM is a poxviral vector-based vaccine consisting of a priming dose of recombinant vaccinia followed by five or six recombinant fowlpox boosts. 21, 22 Both the vaccinia and fowlpox vectors are engineered to express PSA and three costimulatory molecules (TRICOM) designed to enhance the immune response. PSA-TRICOM is an off-the-shelf vaccine that can be generated in large quantities. Frozen doses are simply thawed and injected into the patient, making PSA-TRICOM a logistically simple yet immunologically advanced vaccine. Several early trials demonstrated that the prime-and-boost regimen was well-tolerated, with toxicities consisting mainly of fevers and injection-site reactions. [23] [24] [25] [26] [27] In a single-arm phase II trial of PSA-TRICOM, patients with mCRPC (n = 32) had a median OS of 26.6 months. Thirteen of 29 evaluable patients had a greater than twofold increase in PSA-specific T-cell immune response by ELISPOT assay (interferon-g secretion in response to PSA) and an association between magnitude of immune response and improved OS was observed (P = 0.055). The study also suggested that patients with more indolent disease characteristics based on predicted survival derived the most benefit from vaccine. 28 In a second multicenter phase II trial, 125 men were randomized 2:1 to receive vaccine or placebo, respectively. As in the sipuleucel-T trials, there was no difference in terms of TTP. However, a mature follow-up showed that PSA-TRICOM conferred significantly improved OS (25.1 vs 16.6 months; HR 0.56; 95% CI 0.37-0.85) and a 3-year survival of 30 vs 17% for placebo. 29 In addition, the presence of a preexisting antibody to a glycoprotein antigen in the vector was associated with improved outcome in patients who received PSA-TRICOM. 30 This may result, in part, from the presence of a blood group A-like glycan on the surface of poxviruses that is presumably transferred from the chicken embryo dermal cells used as host cells in vaccine production. This glycan may help to optimize uptake of the poxviral vaccine by APCs.
These phase II trials suggested tumor-specific CTL responses and prolonged OS in patients treated with PSA-TRICOM. An international phase III randomized, placebo-controlled trial of PSA-TRICOM is currently enrolling 1200 patients with asymptomatic or minimally symptomatic mCRPC, with OS as the primary endpoint. 31 Patients are randomized to receive either PSA-TRICOM with adjuvant GM-CSF, PSA-TRICOM with placebo GM-CSF or double placebo. Results of this trial are eagerly anticipated.
GVAX
Two phase III clinical trials of the allogeneic cell-based vaccine GVAX have had disappointing results. 32, 33 The vaccine is based on a platform of irradiated hormone-sensitive (LNCaP) and hormone-resistant (PC-3) prostate cancer cell lines genetically modified to secrete GM-CSF. Early clinical data suggesting clinical benefit led to two phase III trials of GVAX. VITAL-1 randomized patients with asymptomatic mCRPC to vaccine or docetaxel-prednisone, while VITAL-2 randomized symptomatic men to receive docetaxel or docetaxel plus GVAX. At a planned interim analysis, VITAL-2 demonstrated a trend towards more deaths in the experimental arm and shorter median OS, leading to the trial's closure. These findings prompted a futility analysis of VITAL-1. When results suggested a <30% chance of improved OS with GVAX, that trial was terminated as well. It is unclear whether the failure to demonstrate clinical benefit reflects a flaw in trial design or a true lack of vaccine efficacy. Preclinical data suggesting that combining vaccines with immune checkpoint inhibitors may substantially augment a limited antitumor response 34 led to a recent trial on the safety and feasibility of combining GVAX and ipilimumab. 35 Exploratory T-cell monitoring of the 28 patients enrolled on this phase I/II dose escalation/ expansion trial found that patients with higher CTLA-4 expression on CD4 cells prior to treatment was associated with prolonged OS after therapy (46.5 vs 21 months, HR, 0.271, 95% CI, 0.079-0.931, P = 0.036). 36 It is unclear whether this survival advantage is due to the specific use of antibodies against CTLA-4, versus a reflection of a more activated T-cell state, which would lead to improved clinical outcome regardless of the type of immunotherapy. However, the identification of potential biomarkers for clinical efficacy is a key consideration given the unique profile of immune-related adverse events (irAEs).
IPILIMUMAB
Ipilimumab, a fully human anti-CTLA-4 monoclonal antibody, is a first-in-class immune checkpoint inhibitor. CTLA-4, the most extensively studied immune checkpoint molecule, is expressed on CTLs after activation by APCs. The CTLA-4 receptor on CTLs is a negative regulator of T-cell activation that outcompetes CD28 for binding to B7 on APCs. In contrast to CD28/B7 binding, which acts as a costimulatory signal, the binding of CTLA-4 by ipilimumab removes the physiologic brake, augmenting the immune response by blocking the interaction of CTLA and B7. 9 Ipilimumab was FDA-approved for the treatment of relapsed metastatic melanoma after demonstrating improved OS in a phase III trial. 10 Patients were randomized to receive ipilimumab plus a glycoprotein vaccine (gp100), ipilimumab alone or gp100 alone. OS significantly increased in patients given ipilimumab. Patients in the ipilimumab-alone arm showed improved median OS relative to gp100 alone (10.1 vs 6.4 months, HR, 0.68; 95% CI, 8.0-13.8), while patients receiving ipilimumab plus gp100 had a median OS of 10.0 months (HR, 0.66; 95% CI 8.5-11.5). Interestingly, there was no significant difference in median TTP among the three arms, similar to results from the sipuleucel-T and PSA-TRICOM trials. Consistent with earlier clinical trials, ipilimumab's toxicity profile included a wide range of irAEs, thought to be caused by a breaking of tolerance to other host tissues, allowing for collateral damage by activated CTLs. 37, 38 Common irAEs included enterocolitis, hepatitis, dermatitis and endocrinopathies, most of which could be medically managed.
Phase III trials of ipilimumab are ongoing in both chemotherapy-naïve and chemotherapy-refractory mCRPC, based on the results of early-phase studies. In an initial phase I/II study, patients with mCRPC received ipilimumab with or without radiation therapy. In the phase I component, with safety as the primary endpoint, side effects were similar to those seen with ipilimumab alone in patients with melanoma. In the phase II component, which examined preliminary evidence of efficacy, 26% of patients had a PSA decline of ≥50% over the course of the study. One patient had a complete response wherein PSA normalized and an initially large prostatic lesion became undetectable. 39 These results led to two ongoing phase III trials of ipilimumab in patients with mCRPC. The first randomizes chemotherapy-naïve patients to ipilimumab alone vs. placebo. 40 The second compares limited radiation plus ipilimumab vs limited radiation plus placebo in patients previously treated with chemotherapy. 41 Results of this trial were recently presented at the European Cancer Congress, with median OS favoring ipilimumab over placebo (11.2 vs 10 months; HR 0.85, 95% CI 0.72-10.00), though statistical significance was not achieved (P = 0.053). Interestingly, median progression-free survival also favored ipilimumab over placebo (HR 0.70, 95% CI 0.61-0.82), as did PSA declines of ≥50% in evaluable patients (13.1% vs 5.3%).
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A PARADIGM SHIFT Phase III trials of sipuleucel-T and ipilimumab in melanoma, along with the randomized phase II trial of PSA-TRICOM, demonstrated significant improvement in OS with no evidence of short-term clinical benefit (Figure 1) , although preliminary data from a trial of ipilimumab suggests a possible improvement in progression-free survival, a secondary endpoint in that study. 10, 15, 29, 42 This class effect highlights a key difference between the mechanisms of action of immunotherapy and traditional cytotoxic therapies. While conventional therapies directly target the tumor and its microenvironment, therapeutic vaccines and immune checkpoint inhibitors target the immune system, which subsequently targets the tumor. Following administration of therapeutic vaccines and other immunotherapies, the combination of immunogenic tumor targeting and antigen cascade can lead to a delayed yet prolonged clinical response that lasts over a period of weeks to months. 43 While the initial immune response to a single TAA is quite brisk, the activated immune response may in turn lead to the development of long-lived memory cells that can sustain clinical benefit beyond the period of treatment. 44 This phenomenon allows for a broadened immune response over time, even as the tumor mutates to present antigens not included in the vaccine. This is another key contrast to conventional therapies, to which the body does not mount an evolving response and may even become resistant ( Table 1) .
Alternative strategies for assessing the delayed yet prolonged response to immunotherapy are emerging, based on a new understanding of tumor-growth equilibrium in response to vaccine. Tumor growth rate is influenced by intrinsic tumor biology as well as extrinsic factors such as chemotherapy. While conventional cytoreductive therapy reduces tumor burden during treatment, the response is transient. When chemotherapy is discontinued, tumor growth typically returns to its pretreatment rate. On the other hand, immunotherapy may reset the tumor-growth equilibrium. The continued immunologic pressure exerted by effector cells slows the rate of tumor growth over time. 45 Recent data from prostate cancer vaccine trials at the National Cancer Institute suggest that tumor growth slows after treatment with vaccine. 46 A retrospective analysis evaluated patients receiving chemotherapy, hormonal therapy and immunotherapy. In patients who received chemotherapy, tumor burden 
The concept that immunotherapy has the potential to induce a sustained immune response and slow the tumor growth rate without short-term benefit in TTP is supported by results from late-phase clinical trials of sipuleucel-T and PSA-TRICOM in mCRPC and ipilimumab in melanoma. Two trials in earlier-stage disease have also provided supportive evidence that vaccine slows the rate of tumor growth, as measured by PSA doubling time (PSA DT). In the PROTECT trial, patients with nonmetastatic castration-sensitive prostate cancer and normal testosterone were randomized 2:1 to receive sipuleucel-T or placebo after 3-4 months of androgen-deprivation therapy (ADT). 20 Patients who received sipuleucel-T had a 48% longer PSA DT after testosterone normalization (155 vs 105 days; P = 0.038), supporting the notion that therapeutic cancer vaccines modulate tumor growth rates over time. A second trial evaluated patients with recurrent prostate cancer but no metastasis (stage D0). Patients were treated with PSA-TRICOM monthly for 3 months and then once every 3 months. In a post hoc analysis, patients treated with vaccine had an improvement in PSA DT of 4.4-7.7 months (P = 0.002), further suggesting the ability of vaccine to reset tumor-growth equilibrium. 47 Evidence of immunogenic modulation of tumor growth over time suggests that the greatest clinical benefit accrues to patients who receive vaccine early in the disease course. This is supported by a retrospective analysis of baseline PSA values from the IMPACT trial, which found that patients in the lowest PSA quartiles (≤22) had the greatest improvements in survival (HR 0.51). 19 HRs increased with PSA, further suggesting that greater benefit was seen in patients treated earlier in the course of disease. Conversely, administering immunotherapy in later-stage disease is associated with worse outcomes. Analyses of OS curves in randomized, controlled studies of therapeutic vaccines have shown a delayed separation, with no evidence of benefit for the first 6-12 months. Thus, patients destined to die within the first 6 months to a year after receiving vaccine derived no benefit.
1 These data influenced the decision to enroll in the ongoing phase III trial of PSA-TRICOM only those patients with a life expectancy of >1 year. Analysis of retrospective data from the IMPACT trial detected a delayed separation in the time to first opioid analgesic use in patients who received vaccine vs those who did not, 16 further supporting the notion that starting immunotherapy earlier has a greater impact on more disease-specific outcomes such as OS.
There is also evidence to suggest that changes in PSA kinetics may impact clinical endpoints such as metastasis-free survival. In a post hoc analysis of 146 men treated in four phase II trials investigating nonhormonal agents for biochemically recurrent nonmetastatic prostate cancer, changes in PSA DT and change in (log) PSA slope were associated with metastasis-free survival. Specifically, men whose PSA DT increased after study entry or whose PSA slope decreased had improved metastasis-free survival. While retrospective, this study gives credence to the value of PSA kinetics in determining clinical endpoints in trial design. 48 
BIOMARKERS
While our understanding of the fundamental differences between immunotherapies and standard cytoreductive treatments has grown, there is still an urgent need for definitive biomarkers to assess the short-term benefits of immunotherapies. Without clear markers of short-term benefit, such as reduced tumor volume or PSA decline, practitioners are faced with difficult choices as they integrate immunotherapy into treatment for prostate cancer. The absence of objective measures of a vaccine's effectiveness makes deciding whether to continue treatment or move on to the next course of therapy difficult at best. 49 Theoretically, markers of immune activation may be evaluable in blood samples weeks or months after administration of vaccine. Retrospective data evaluating immune parameters in patients treated with sipuleucel-T suggest a correlation between the magnitude of cumulative APC activation and OS. 17 An ongoing open-label phase II trial (OpenAct) will extensively evaluate cellular and humoral activation following treatment with sipuleucel-T. 50 Similarly, improved clinical outcomes have been associated with CTL response in patients treated with PSA-TRICOM. 28 Subsequent analysis also noted a significant correlation with survival in patients with prevaccination antibodies to a glycoprotein antigen in the vector. 30 The ongoing phase III trial of PSA-TRICOM in mCRPC aims to evaluate immune endpoints and provide further data supporting vaccines' ability to alter growth rate while providing clinically significant improvement in OS. However, it must be noted that, to date, no surrogate biomarkers for clinical outcomes in patients treated with immunotherapy have been identified.
Next steps: optimal combinations and sequencing of therapy
One apparent drawback of immunotherapy is the fact that other treatment modalities produce measurable tumor response in addition to improving OS. Thus, the maximum clinical benefit of immunotherapies may only be realized when they are combined or sequenced with conventional treatments for prostate cancer, preferably early in the course of disease when both tumor burden and tumor-induced tolerance are minimal. 51, 52 Dead or dying cancer cells may release antigens that stimulate an immune response in a process known as immunogenic cell death. 53 There is strong evidence that combining immunotherapies for prostate cancer with conventional treatments such as chemotherapy and radiation can enhance the immune response by altering the tumor phenotype. This immunogenic modulation renders cells more sensitive to CTL killing, further supporting the rationale for combined treatment regimens. 54, 55 Preclinical data have demonstrated that combining vaccine and docetaxel induces enhanced immune activity compared with either treatment alone. 56 In a study of patients with metastatic breast cancer, docetaxel combined with a poxviral vaccine targeting mucin-1 and carcinoembryonic antigen prolonged TTP (6.6 vs 3.8 months, P = 0.12, HR 0.67). 57 Radiation therapy can also enhance antigen expression and immune-mediated tumor-cell killing. 58, 59 The potential value of 60, 61 An interim analysis of a radiation combination trial using the radioisotope samarium-153 (Sm-153) combined with PSA-TRICOM showed prolonged TTP compared to treatment with Sm-153 alone. The combination of vaccine and Sm-153 was well-tolerated, with similar toxicity to Sm-153 alone, further supporting the rationale for combining vaccine and radiation. 62 ADT is a mainstay of treatment for prostate cancer, having been shown in preclinical models to potentiate antitumor immunity via immune conditioning. 63 Increasing data suggest that ADT can augment the immune response by increasing CTL infiltration of the prostate. 64 ADT has also been shown to increase thymic production of naïve T cells, which can be harnessed by immunotherapy and directed at PSA. 65 Other data suggest that ADT mitigates immune tolerance, allowing immunotherapies to target cancer cells that overexpress self-antigens. 66 While the optimal sequencing of immunotherapy with ADT is unclear, combining ADT with immunotherapy for a defined period of time may help to eradicate residual prostate cancer cells once ADT is discontinued.
To explore this possibility, a phase II randomized trial is ongoing in which 68 patients with biochemically recurrent prostate cancer are randomized to receive sipuleucel-T either 6 weeks before or 12 weeks after a year-long course of ADT. 67 Analysis of antitumor immune response will establish which sequence is more effective. The study will also compare PSA progression and metastasis-free survival in the two arms. An interim analysis has suggested an increase in antigen-specific responses and in vivo cytokines in the arm in which ADT is followed by vaccine, providing evidence for a possible improvement in antitumor response when ADT is administered first. 68 Final results will further elucidate the optimal sequencing of immunotherapy with ADT.
PSA-TRICOM has also been studied in combination with standard therapies. A phase II study randomized 42 men with nonmetastatic CRPC to receive PSA-TRICOM or ADT, with an option to cross over to combined therapy at disease progression. 69 This study suggested improved survival in patients who received vaccine prior to ADT. Promising data have also emerged from an ongoing trial evaluating flutamide with PSA-TRICOM in nonmetastatic CRPC. Interim TTP analysis favored the combination of PSA-TRICOM and flutamide compared to flutamide alone (192 vs 108 days). 70 GVAX is also being studied in combination with cyclophosphamide and ADT in the neoadjuvant setting, based on preclinical data suggesting augmented antitumor immune responses if low-dose cyclophosphamide precedes vaccine. 1 The ongoing neoadjuvant trial randomizes patients to cyclophosphamide and GVAX followed by ADT versus ADT alone prior to radical prostatectomy. 72 Primary outcome measures include comparison of intraprostatic CD8 + T-cell infiltration between treatment arms.
The advent of novel hormonal agents such as abiraterone and enzalutamide has sparked interest in combining these therapies with immune-based approaches. An ongoing phase II trial randomizes men with mCRPC to receive sipuleucel-T followed by abiraterone in combination with prednisone or to concurrent therapy with both of these agents. 73 This addresses an important issue regarding sequencing, as preclinical data suggest that immunotherapy may be optimally effective when administered before androgen ablation. 74 Abiraterone, a CYP17 inhibitor FDA-approved for use in mCRPC, suppresses levels of circulating androgen. Suppression of the androgen axis via abiraterone may be immunostimulatory, suggesting that abiraterone plus sipuleucel-T could be synergistic. At the same time, administering abiraterone with prednisone may theoretically blunt an immunologic response; however, previous data suggest that memory cells are relatively resistant to steroid-induced killing compared with naïve cells. 75 An interim analysis of this study shows similar humoral and cellular responses to sipuleucel-T in both the concurrent and sequential arms, suggesting that the steroids when given with abiraterone did not appear to blunt the immune response. This is in line with previous observations about the addition of glucocorticoids and immune response. 75, 76 Additionally, preliminary findings suggest that sipuleucel-T is well-tolerated in combination with concurrent or sequential abiraterone with prednisone. 77 Recently reported data on 64 patients from this phase II trial indicate that sipuleucel-T can be successfully manufactured during concurrent abiraterone and prednisone without affecting product potency and immunologic prime-boost response. 78 FDA approval of enzalutamide for the treatment of chemotherapyrefractory mCRPC has stimulated interest in using this novel androgen receptor antagonist (ARA) in earlier-stage prostate cancer and in combination with immunotherapy, given its favorable side-effect profile. 79 This next-generation ARA binds to the androgen receptor with greater affinity than first-generation ARAs and prevents downstream effects, including nuclear translocation, DNA binding and signaling to coactivators. Another important characteristic of this ARA is that, unlike the androgen-biosynthesis inhibitor abiraterone, enzalutamide does not require daily prednisone. Patients with nonmetastatic castration-sensitive prostate cancer are currently being enrolled in a phase II trial that randomizes men to receive a 3-month course of enzalutamide with or without PSA-TRICOM. 80 The primary endpoint of this study is to determine the vaccine's effect on PSA growth kinetics after enzalutamide is discontinued. This proof-of-concept study will help to define the benefits of combining ADT and immunotherapy. A similar study is being conducted in chemotherapy-naïve patients with metastatic disease ( Table 2) . 81 
Combining immunotherapies (immunogenic intensification)
Combining immunotherapies could potentially generate a greater immune response and enhanced antitumor activity. 82 Previous studies have shown evidence of enhanced clinical outcomes without increased toxicity. For example, combining ipilimumab and PSA-TRICOM provides directed T-cell activation while removing physiologic brakes on the immune system, allowing for a more robust CTL response. A phase I study treated 30 patients with docetaxel-refractory or chemotherapy-naïve mCRPC with a fixed dose of PSA-TRICOM in conjunction with escalating doses of ipilimumab given at monthly intervals. Rates of irAEs in patients receiving the combination therapy were similar to those reported with ipilimumab alone, including endocrinopathies and colitis, but no dose-limiting toxicities were observed. Only 1/6 patients previously treated with chemotherapy had a PSA decline from baseline. Of the 24 patients who were chemotherapy-naïve, 14 (58%) had PSA declines, six of which (25%) were >50%. In addition, the median OS of patients treated with this combination (34.4 months) appears to be greater than patients treated with vaccine alone. 83 These hypothesis-generating data suggest that intensification of immune-based therapies may improve clinical outcomes.
Based on preclinical models suggesting synergy between ipilimumab and the whole tumor cell vaccine GVAX, 84 a phase I dose-escalation trial enrolled chemotherapy-naïve patients with mCRPC and treated them with GVAX and concurrent intravenous ipilimumab for 24 weeks. Approximately 29% of patients experienced grade 3 irAEs; for one patient, 5 mg kg −1 of ipilimumab led to a dose-limiting toxicity. PSA declines of >50% were observed in 25% of men, with a median OS of 29.2 months. 35 A recent preclinical study explored optimal sequencing of CTLA-4 blockade with cell-based immunotherapy. 85 Early safety and efficacy studies of ipilimumab plus vaccine opened the door for future trials of combination therapy with immune checkpoint inhibitors, and provided the rationale for combining prostate cancer vaccines with monoclonal antibodies targeting programmed cell death protein 1. Early clinical trials of this novel immune checkpoint inhibitor have suggested antitumor activity with less frequent and severe irAEs than are reported with ipilimumab.
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CONCLUSIONS
Immunotherapies have contributed significantly to the evolving landscape of prostate cancer treatment. Ongoing phase III trials of PSA-TRICOM and the immune checkpoint inhibitor ipilimumab may soon broaden the scope of immunotherapies available to patients with mCRPC. Current strategies are also exploring optimal combinations and sequencing of immunotherapies with conventional treatments. Integration of immunotherapy into standard treatment regimens has been hampered by the lack of short-term measures of objective response. However, an evolving understanding of these agents' effects on tumor growth rate equilibrium, coupled with well-designed clinical trials evaluating immune endpoints and growth rate kinetics, may soon provide answers to this dilemma. 
